Abstract
SIRT1, which is highly homologous to yeast silent information regulator 2, has recently garnered tremendous attention because of its various regulatory effects in several pathological conditions. Numerous studies have found that SIRT1 is highly expressed in a broad range of tumours compared with the paracancerous tissue. However, the role of SIRT1 in malignancies has yet to be systematically elucidated, and its use as a promising biomarker or therapeutic target for tumours has not been well-reported. Herein, we focus on the roles of SIRT1 in cancers and summarise the potential use of SIRT1 as a promising tumour biomarker or therapeutic target.
| Original language | English |
|---|---|
| Pages (from-to) | 1046-1052 |
| Number of pages | 7 |
| Journal | Journal of Drug Targeting |
| Volume | 27 |
| Issue number | 10 |
| DOIs | |
| State | Published - 26 Nov 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- SIRT1; tumour diagnosis; tumour prognosis; tumour biomarker; therapeutic target
Fingerprint
Dive into the research topics of 'SIRT1: a potential tumour biomarker and therapeutic target'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver